Desidustat

Last updated

Desidustat
Desidustat.svg
Clinical data
Other namesZYAN1
Identifiers
  • 2-[[1-(Cyclopropylmethoxy)-4-hydroxy-2-oxoquinoline-3-carbonyl]amino]acetic acid
CAS Number
UNII
Chemical and physical data
Formula C16H16N2O6
Molar mass 332.312 g·mol−1
3D model (JSmol)
  • C1CC1CON2C3=CC=CC=C3C(=C(C2=O)C(=O)NCC(=O)O)O
  • InChI=1S/C16H16N2O6/c19-12(20)7-17-15(22)13-14(21)10-3-1-2-4-11(10)18(16(13)23)24-8-9-5-6-9/h1-4,9,21H,5-8H2,(H,17,22)(H,19,20)
  • Key:IKRKQQLJYBAPQT-UHFFFAOYSA-N

Desidustat (INN, also known as ZYAN1) is a drug for the treatment of anemia of chronic kidney disease. This drug with the brand name Oxemia is discovered and developed by Zydus Life Sciences. [1]

Contents

Mechanism of action

Desidustat reduces the requirement of recombinant erythropoietin (EPO) in anemia, and decreases EPO-resistance, by reducing IL-6, IL-1β, and anti-EPO antibodies. [2]

Clinical Trials

Clinical trials on desidustat have been done in India and Australia. [3]

Potential additional indications

Desidustat has been studied for use in conditions beyond anemia of chronic kidney disease, including chemotherapy-induced anemia, inflammation-induced anemia, and acute kidney injury. It is also being evaluated in clinical trials for sickle cell disease and has been suggested as a treatment for complement-mediated diseases and stroke in chronic kidney disease patients. [4]

Society and culture

Regulatory approvals

The subject expert committee of CDSCO has recommended the grant of permission for manufacturing and marketing of Desidustat 25 mg and 50 mg tablets in India, based on some conditions related to package insert, phase 4 protocols, prescription details, and GCP. [5]

Market and commercialization

Zydus Lifesciences and Sun Pharmaceuticals have entered an agreement in October 2023 to co-market Desidustat. Sun Pharma will sell the drug as Rytstat, while Zydus will continue to sell it as Oxemia. [6]

References

  1. ↑ Joharapurkar A, Pandya V, Patel H, Jain M, Desai R (2024). "Desidustat: a novel PHD inhibitor for the treatment of CKD-induced anemia". Frontiers in Nephrology. 4: 1459425. doi: 10.3389/fneph.2024.1459425 . PMC   11534831 . PMID   39502472.
  2. ↑ Joharapurkar AA, Patel VJ, Kshirsagar SG, Patel MS, Savsani HH, Kajavadara C, et al. (2022). "Prolyl hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive state". Current Research in Pharmacology and Drug Discovery. 3: 100102. doi:10.1016/j.crphar.2022.100102. PMC   9096675 . PMID   35570856.
  3. ↑ Kansagra KA, Parmar D, Jani RH, Srinivas NR, Lickliter J, Patel HV, et al. (January 2018). "Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers". Clinical Pharmacokinetics. 57 (1): 87–102. doi:10.1007/s40262-017-0551-3. PMC   5766731 . PMID   28508936.
  4. ↑ Kaur H, Pandey N, Chandaluri L, Shaaban N, Martinez A, Kidder E, et al. (February 2025). "Prolyl hydroxylase inhibitor desidustat improves stroke outcomes via enhancing efferocytosis in mice with chronic kidney disease". Experimental Neurology: 115181. doi:10.1016/j.expneurol.2025.115181.
  5. ↑ CDSCO SC. "SEC meeting to examine IND proposals, dated 29.12.2021". CDSCO website Govt of India. CDSCO. Retrieved 19 January 2022.
  6. ↑ "Sun Pharma, Zydus to co-market drug for CKD-induced anaemia". The Times of India. 31 October 2023.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.